tiprankstipranks
Advertisement
Advertisement
Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback
PremiumThe FlyMonte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback
14d ago
Buy Rating Maintained on Monte Rosa as Diversified Degrader Pipeline and Novartis Partnership Offset ZEUS Cardiovascular Setback
Premium
Ratings
Buy Rating Maintained on Monte Rosa as Diversified Degrader Pipeline and Novartis Partnership Offset ZEUS Cardiovascular Setback
14d ago
Monte Rosa Therapeutics price target lowered at Jefferies after Novo trial miss
Premium
The Fly
Monte Rosa Therapeutics price target lowered at Jefferies after Novo trial miss
14d ago
Monte Rosa Therapeutics to present preclinical data on MRT-55811
PremiumThe FlyMonte Rosa Therapeutics to present preclinical data on MRT-55811
4M ago
Monte Rosa Therapeutics price target lowered to $30 from $34 at Guggenheim
Premium
The Fly
Monte Rosa Therapeutics price target lowered to $30 from $34 at Guggenheim
5M ago
Monte Rosa Therapeutics reports Q4 collaboration revenue $2.78M
Premium
The Fly
Monte Rosa Therapeutics reports Q4 collaboration revenue $2.78M
5M ago
Monte Rosa Therapeutics files automatic mixed securities shelf
PremiumThe FlyMonte Rosa Therapeutics files automatic mixed securities shelf
6M ago
Monte Rosa Therapeutics price target raised to $37 from $27.50 at Piper Sandler
Premium
The Fly
Monte Rosa Therapeutics price target raised to $37 from $27.50 at Piper Sandler
7M ago
Monte Rosa Therapeutics Prices $300 Million Public Offering
Premium
Company Announcements
Monte Rosa Therapeutics Prices $300 Million Public Offering
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100